Phenyl Derivatives as Selective CB2 Agonists for Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions such as ischemia/reperfusion injury, chronic pain, atherosclerosis, and fibrosis lack effective therapies due to inadequate modulation of Cannabinoid Receptor 2 (CB2), which is crucial for reducing inflammation and tissue damage.
Innovation Solution
Development of a compound of formula (I) that selectively binds to and modulates the CB2 receptor, reducing CB1 receptor activity, thereby providing therapeutic benefits for conditions like diabetic retinopathy, retinal vein occlusion, and uveitis, while minimizing side effects on the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective cannabinoid receptor agonists are used, then anti-inflammatory and analgesic effects are achieved, but unwanted side effects occur due to CB1 receptor activation in the central nervous system
Solution Approach 1:
The patent applies local quality by creating receptor-selective ligands that exhibit different binding affinities and functional activities at CB1 and CB2 receptors. The compound structure is designed to preferentially activate CB2 receptors (peripheral anti-inflammatory/analgesic effects) while minimizing CB1 receptor (central nervous system) activity, thereby achieving therapeutic effectiveness without unwanted CNS side effects.
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular parameters of cannabinoid receptor ligands, including substituting specific atoms or groups at defined positions in the molecular structure. These structural modifications alter the binding affinity and selectivity parameters, enabling differentiation between CB1 and CB2 receptor interactions to achieve peripheral selectivity.
2Reliability
If CB2 receptor agonists are developed to reduce inflammation and tissue damage, then therapeutic benefits are achieved for conditions like ischemia/reperfusion injury and fibrosis, but the complexity of compound synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the complex synthesis process into discrete, manageable steps through a stepwise synthesis approach. The method segments the construction of complex cannabinoid receptor ligands into sequential transformations from simpler precursors, enabling systematic development and optimization of CB2-selective compounds while reducing overall synthesis complexity.
Solution Approach 2:
The patent employs intermediary compounds as mediators in the synthesis pathway. Intermediate structures serve as bridges between simple starting materials and complex final CB2 agonists, facilitating stepwise construction and allowing for optimization at each stage while maintaining overall synthesis efficiency.
3Adaptability or versatility
If selective CB2 receptor modulators are created, then targeted therapy for specific conditions is achieved, but the development time and resource requirements increase
Solution Approach 1:
The patent applies preliminary action by performing pre-clinical studies and optimization work before initiating clinical trials. The systematic development approach includes preliminary structural optimization, selectivity profiling, and safety assessments that are completed in advance, thereby preparing the compound for efficient transition to clinical development and reducing overall development time.
Solution Approach 2:
The patent employs universality by designing a platform approach that can generate multiple CB2-selective ligands with different pharmacological profiles. This multi-functional platform enables the same synthetic methodology to produce compounds for various indications (ischemia/reperfusion injury, fibrosis, pain, inflammation), thereby reducing development time through knowledge and methodology transfer across different therapeutic areas.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively reduces inflammation and tissue damage, offering potential therapeutic benefits for various conditions including ischemia/reperfusion injury, chronic pain, and fibrosis by selectively targeting the CB2 receptor, thus providing a more targeted and effective treatment approach.
Implementation Method 1
The compound effectively reduces inflammation and tissue damage, offering potential therapeutic benefits for various conditions including ischemia/reperfusion injury, chronic pain, and fibrosis by selectively targeting the CB2 receptor
Implementation Method 2
Development of a compound of formula (I) that selectively binds to and modulates the CB2 receptor, reducing CB1 receptor activity
Data Source
AI summary
The invention relates to a compound of formula (I)wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.